The appearance of GVHD and the relapse of the neoplastic disease are still the main complications after allo hematopoietic SCT (allo-HSCT). Immunotherapy with donor T-lymphocyte infusion is an effective method for treating relapse after allo-HSCT, but the therapeutic graft versus tumor (GVT) effect is often associated with the appearance of acute GVHD 1 Many strategies have been developed to separate both effects, mainly by targeting tumorassociated proteins or by exploiting the presence of donorrecipient immunogenetic mismatches.
mHAs have been studied to develop immunotherapeutic approaches, based on their tissue distribution. In this sense, hematopoietic-restricted Ags such as HA-1 or HA-2 have been identified as attractive potential targets because of the description of cytotoxic-T cell clones directed against these mHAs driving the GVT effect. 2, 3 However, the correlation between HA-1 and GVHD is a matter of debate. 4, 5 An increased risk of acute GVHD has been also observed in the presence of a HA-8 or H-Y Ags mismatch. 6, 7 Oostvogels et al. 8 have recently identified a new mHAg, UTA2-1. This Ag is restricted by HLA-A*02:01, and its expression is restricted to the hematopoietic tissue, with a relevant immunogenic expression on malignant cells. The authors suggest that these properties make this mHAg a good candidate for consideration as an immunotherapeutic target. UTA2-1 is encoded by rs2166807 on gene C12orf35, (chromosome 12), and the codified-protein function is currently unknown. This singlenucleotide polymorphism results in two different UTA2-1 peptides differing in the third amino acid position: QLPNSVLTL (UTA2-1 P ) and QLLNSVLTL (UTA2-1 L ). The UTA2-1 L is the immunogenic peptide, and the UTA2-1 mismatch is defined by the presence of UTA2-1 L allele in the host and its absence in the donor, but only in patients positive for the HLA-A*02:01 restriction element.
To determine the impact of UTA2-1 mismatch on clinical outcome after allo-HSCT from an HLA-identical sibling donor we retrospectively analyzed 1041 patient/donor pairs. The infused graft was non T-cell depleted in all cases. Two groups were defined according to the presence or absence of the UTA2-1 mismatch (Table 1) . Only HLA-A*02:01 were considered for UTA2-1 typing, with the rest being considered as negative for UTA2-1 mismatch because of the absence of the required HLA restriction molecule.
Genotyping of the UTA2-1 polymorphism was performed by PCR real-time allele discrimination according to the manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). As internal controls, we genotyped 21 cell lines from the International Histocompatibility Working Group (IHWG) (http://www.ihwg.org/ hla/index.html) previously typed for other mHAs 9 (Table 2A) . We confirmed the UTA2-1 genotyping by sequencing samples from IHWG using primers previously described. 9 Allele frequencies and genotypes were formulated by direct counting (Table 2B) ; the observed frequencies were in accordance with the frequencies previously described in www.ensembl.org for a European population. The cohort was in Hardy-Weinberg equilibrium (1.27; P = 0.05).
Homogeneity between groups was evaluated by means of the t-test for continuous variables and the Χ 2 -test for categorical variables. OS and disease-free survival (DFS) were determined by Kaplan-Meier curves, and compared by the log-rank test. Cumulative-incidence estimates were used to explore differences in acute GVHD, TRM and relapse incidence. Multivariate analysis was performed using the Cox regression model. All the variables with a P-value at or below 0.2 in the univariate analysis were included in the multivariate analysis.
The UTA2-1 mismatch was detected in 20 cases (1.9% of the cohort). In univariate analysis, the presence of the UTA2-1 mismatch had no effect neither on OS (49.5% in the presence of UTA2-1 mismatch vs 46.7%; P = n.s.) nor on DFS (39.2% vs 40.6%; P = n.s.). Cumulative incidence of acute GVHD grades II-IV was also similar (26.7% vs 35.5%; P = n.s.). The univariate analysis showed a Abbreviations: CSP = cyclosporine; MDS = myelodysplastic syndrome; MMF = mycophenolate mofetil. Gender mismatch was considered as female donor/male recipient. Advanced disease was considered for patients with acute leukemia beyond first CR, CML beyond first chronic phase and progressive disease for patients with MDS, multiple myeloma or lymphoma.
Bone Marrow Transplantation (2015) 50, 298-300 © 2015 Macmillan Publishers Limited All rights reserved 0268-3369/15 www.nature.com/bmt trend towards statistical significance when considering the incidence of acute GVHD grades III-IV (26.7% vs 14.9%: P = 0.186). However, multivariate analysis failed to yield statistically significant differences (P = 0.218). The covariates included in this multivariate analysis were: age, diagnosis, disease stage, gender mismatch, stem cell source, immunosuppressive regimen and UTA2-1 mismatch. We did not find differences in the incidence of chronic GVHD (52.9% vs 45.6%; P = n.s.), TRM at 2 years (33.1% vs 23%; P = n.s.) or relapse incidence (25.7% vs 30.8%; P = n.s.).
To determine if the presence of a UTA2-1 mismatch was associated or not with the clinical outcome, we performed a second analysis including only a homogeneous cohort with the HLA-A*02:01 positive patient/donor pairs (n = 456). Again, we did not detect any statistical significance for OS (49.5% vs 48.6%; P = 0.961), DFS (39.2% vs 42%; P = 0.972), relapse (41.1% vs 37.6%; P = 0.617), TRM (33.1% vs 30%; P = 0.525), grades II-IV acute GVHD (26.7% vs 35.4%; P = 0.397), grades III-IV acute GVHD (26.7% vs 15.7%; P = 0.236) or chronic GVHD (52.9% vs 45.6%; P = 0.622).
As it has been suggested that the anti-leukemic effect of hematopoietic mHA mismatching can only become clinically evident in recipients with GVHD, 10 we analysed if the presence of an UTA2-1 mismatch influenced the clinical outcome in the presence or absence of both acute and chronic GVHD, but we also failed to detect statistically significant differences in relapse incidence, OS, DFS or TRM.
Our results show that UTA2-1 mismatch is an infrequent condition in allo-HSCT from HLA-identical-sibling donors, and the presence of this mismatch does not seem to be relevant to the allo-HSCT clinical outcome. This must be taken into account when considering this mHAg as a potential target for immunotherapy approaches. It should be considered that Oostvogels et al. 8 described the presence of specific cytotoxic T-lymphocytes against UTA2-1 in one patient showing a strong GVT response after DLI, and the usefulness of immunotherapeutic approaches directed against UTA2-1 after relapse, in the absence of immunosuppressive treatment, should not be disregarded. Despite the limitations of our study, owing to the low frequency of this mismatch that would require an even higher number of cases to confirm these results, the observed similar incidence of acute GVHD may encourage consideration of the UTA2-1-based immunotherapeutic approaches in terms of safety. Letter to the Editor
